GlaxoSmithKline-Pfizer AIDS Pill May Surpass Bristol’s
According to Bloomberg, a drug developed by GlaxoSmithKline and Pfizer controlled HIV faster and more safely than Bristol-Myers Squibb’s Sustiva in a study, suggesting the experimental medicine may one day be preferred to Bristol’s. Dolutegravir, a product of Glaxo and Pfizer’s ViiV Healthcare joint venture, reduced HIV to undetectable levels in 90 percent of patients after 48 weeks, compared with 82 percent of those who got Sustiva, according to results presented at an AIDS meeting in Rome. Dolutegravir also caused a significantly lower rise in bad cholesterol than Sustiva, at one-twelfth of the dose size. Sustiva is one of three drugs in Gilead Sciences’ Atripla, the world’s best-selling AIDS pill, and brought New York-based Bristol $1.4 billion in sales last year.